| Literature DB >> 27221704 |
Deepak Mittal1, Debottam Sinha2, Deborah Barkauskas3, Arabella Young1, Murugan Kalimutho4, Kimberley Stannard3, Franco Caramia5, Benjamin Haibe-Kains6, John Stagg7, Kum Kum Khanna4, Sherene Loi5, Mark J Smyth8.
Abstract
Adenosine plays an important role in inflammation and tumor development, progression, and responses to therapy. We show that an adenosine 2B receptor inhibitor (A2BRi) decreases both experimental and spontaneous metastasis and combines with chemotherapy or immune checkpoint inhibitors in mouse models of melanoma and triple-negative breast cancer (TNBC) metastasis. Decreased metastasis upon A2BR inhibition is independent of host A2BR and lymphocytes and myeloid cells. Knockdown of A2BR on mouse and human cancer cells reduces their metastasis in vivo and decreases their viability and colony-forming ability, while transiently delaying cell-cycle arrest in vitro The prometastatic activity of adenosine is partly tumor A2BR dependent and independent of host A2BR expression. In humans, TNBC cell lines express higher A2BR than luminal and Her2(+) breast cancer cell lines, and high expression of A2BR is associated with worse prognosis in TNBC. Collectively, high A2BR on mouse and human tumors promotes cancer metastasis and is an ideal candidate for therapeutic intervention. Cancer Res; 76(15); 4372-82. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27221704 DOI: 10.1158/0008-5472.CAN-16-0544
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701